CD2AP deficiency aggravates Alzheimer’s disease phenotypes and pathology through p38 MAPK activation
2024

CD2AP Deficiency and Alzheimer's Disease

Sample size: 134 publication 10 minutes Evidence: high

Author Information

Author(s): Xue Yan-Yan, Zhang Zhe-Sheng, Lin Rong-Rong, Huang Hui-Fen, Zhu Ke-Qing, Chen Dian-Fu, Tao Qing-Qing, Wu Zhi-Ying

Primary Institution: Zhejiang University School of Medicine

Hypothesis

CD2AP deficiency aggravates Alzheimer's disease phenotypes and pathology through p38 MAPK activation.

Conclusion

CD2AP deficiency exacerbates Alzheimer's disease pathology and cognitive deficits through the activation of the p38 MAPK pathway.

Supporting Evidence

  • CD2AP is widely expressed in various regions of the mouse brain, predominantly in neurons.
  • Neuronal knockout of Cd2ap significantly aggravated tau pathology and cognitive deficits in APP/PS1 mice.
  • The knockout of Cd2ap activated p38 MAPK signaling, contributing to increased tau phosphorylation and neuronal apoptosis.
  • Phenotypes of neuronal Cd2ap knockout were ameliorated by a p38 MAPK inhibitor.

Takeaway

When a protein called CD2AP is missing, it makes Alzheimer's disease worse in mice, affecting their memory and brain health.

Methodology

The study used APP/PS1 mouse models with neuron-specific Cd2ap deletion and CD2AP-knockdown SH-SY5Y cell lines to investigate the effects of CD2AP deficiency on Alzheimer's disease.

Limitations

The study primarily focused on young mice, and the effects of CD2AP deficiency in older mice were not evaluated.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/s40035-024-00454-5

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication